BridgeBio is drawing acquisition interest from larger pharma companies, Bloomberg’s Michelle F Davis and Dinesh Nair report, citing people familiar with the matter. Some big drug companies are weighing a potential takeover bid of BridgeBio, the authors say. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BBIO:
- BridgeBio attracting bigger companies’ takeover interest, Bloomberg says
- BridgeBio announces first patient dosed in Phase 1 trial of BBP-398 with OPDIVO
- BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
- BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
- BridgeBio shares preliminary findings on glycosylated alpha-dystroglycan